Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial For Its Arcelis(TM) Personalized Immunotherapy Platform In HIV
May 15th 2008Drug InformationClinical Trials
Argos Therapeutics announced the initiation of a Phase 2a proof-of-concept clinical trial to test the efficacy of its AGS-004 therapy in improving immune control of viral replication in HIV-infected adults. AGS-004 is a product of the Company’s Arcelis? technology, a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
